Stockscreener 앱 받기
77.09
0.93%
-0.72
시장 영업 전:
77.00
-0.09
-0.12%
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme enters license agreement with Incyte - The Pharma Letter
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations - Contract Pharma
Halozyme and Incyte announce global collaboration deal - grafa.com
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development - Yahoo Finance
Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Technology - GuruFocus
Halozyme Therapeutics (HALO) Secures Global Deal with Incyte for Innovative Drug Delivery - GuruFocus
Halozyme partners with Incyte on drug delivery technology By Investing.com - Investing.com Nigeria
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - PR Newswire
Technical Reactions to HALO Trends in Macro Strategies - Stock Traders Daily
Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics (0J2O) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyne Therapeutics (HALO) Is An Undervalued Stock That Keeps Winning In Cancer Treatment - Yahoo Finance
HALO5387960 Bond Profile — Key Metrics - TradingView
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 10% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Halozyme Therapeutics (HALO) Q1 2025 earnings summary - Quartr
Halozyme Therapeutics (HALO) Proxy filing Summary - Quartr
Halozyme Therapeutics (HALO) Q1 2026 earnings summary - Quartr
Halozyme Therapeutics (HALO) AGM 2026 Summary - Quartr
2 Reasons to Like HALO and 1 to Stay Skeptical - Yahoo Finance
Halozyme Therapeutics, Inc. Stock 12‑Month Price Target Cut to $83.44, Implies 6% Upside - TradingView
Halozyme president & CEO Helen Torley sells $153,390 in stock - Investing.com UK
Form 4 Halozyme Therapeutics Inc For: 9 July By Investing.com - Investing.com Nigeria
Halozyme president & CEO Helen Torley sells $153,390 in stock By Investing.com - Investing.com Nigeria
Halozyme (HALO) CEO sells 1,923 exercised shares under Rule 10b5-1 plan - Stock Titan
How Halozyme’s Leadership Shake-Up Around Drug Delivery At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - simplywall.st
Halozyme Therapeutics focuses on drug-delivery partnerships as investors watch Nasdaq biotech sentim - ad-hoc-news.de
Halozyme Therapeutics (HALO) Investor Update Summary - Quartr
Halozyme Therapeutics (HALO) Investor Outlook: Analyzing Growth with 42.20% Revenue Surge - DirectorsTalk Interviews
Halozyme's Q4 earnings miss, higher royalties drive Y/Y revenues - MSN
Halozyme signs collaboration deal with GSK for oncology targets - Investing.com
Halozyme Therapeutics (HALO) Leadership Reset Raises The Question Of Whether The Stock Is Fully Valued - Sahm
Price to sales forward of Halozyme Therapeutics, Inc. – NASDAQ:HALO - TradingView
Halozyme Therapeutics Operating Chief Caudill to Exit - Moomoo
Halozyme announces key executive leadership transition and reorganization - The Globe and Mail
Halozyme stock falls as chief operating officer departs By Investing.com - Investing.com Nigeria
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Halozyme stock falls as chief operating officer departs - Investing.com
Halozyme (NASDAQ: HALO) EVP receives new options, RSUs and RSU vesting - Stock Titan
Halozyme (NASDAQ: HALO) CFO awarded large option and RSU package - Stock Titan
Halozyme (HALO) director sells 1,625 shares in 10b5-1 trades - Stock Titan
Halozyme Therapeutics (HALO) COO Cortney Caudill to depart in management reshuffle - Stock Titan
Halozyme Therapeutics, Inc. Announces Departure of Cortney Caudill as Senior Vice President, Chief Operating Officer - marketscreener.com
Is Halozyme (HALO) Elevating Drug Delivery Leadership to Reframe Its Core Investment Narrative? - Sahm
Halozyme names David Ramsay as president drug delivery - Investing.com UK
Halozyme names David Ramsay as president drug delivery By Investing.com - Investing.com South Africa
Halozyme director Mahesh Krishnan sells $547,800 in stock By Investing.com - Investing.com South Africa
Form 4 Halozyme Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia
Halozyme director Mahesh Krishnan sells $547,800 in stock - Investing.com UK
Halozyme (HALO) director exercises options, sells 7,304 shares under plan - Stock Titan
0.74%
3.77%
자본화:
|
볼륨(24시간):